Jan
25
FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant
The following is a statement from Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research. As we have throughout the COVID-19 pandemic, the U.S. Food and Drug Administration has used the best available science as the virus has evolved to make informed decisions with the health and safety of the American … Read more